Fluorescent TEM-1 β-lactamase with wild-type activity as a rapid drug sensor for in vitro drug screening

Bioscience Reports

Volumn 34, Issue 5, 2014, Pages 523-533

  Cheong, Wing Lam ^a   Tsang, Ming San ^a   So, Pui Kin ^a   Chung, Wai Hong ^a   Leung, Yun Chung ^a   Chan, Pak Ho ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Antibiotics; Bacteria; Drug screening; Inhibitors sensor; lactamase

Indexed keywords

BACTERIA (MICROORGANISMS);

BETA LACTAM; BETA LACTAMASE; BETA-LACTAMASE TEM-1; ESCHERICHIA COLI PROTEIN;

AMINO ACID SUBSTITUTION; CHEMISTRY; ENZYME ACTIVE SITE; ENZYMOLOGY; ESCHERICHIA COLI; GENETIC PROCEDURES; GENETICS; MISSENSE MUTATION; PRECLINICAL STUDY; PROCEDURES;

AMINO ACID SUBSTITUTION; BETA-LACTAMASES; BETA-LACTAMS; BIOSENSING TECHNIQUES; CATALYTIC DOMAIN; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; MUTATION, MISSENSE;

EID: 84949133018     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20140057     Document Type: Article

References (41)

1. McDonough, M. A., Anderson, J. W., Silvaggi, N. R., Pratt, R. F., Knox, J. R. and Kelly, J. A. (2002) Structures of two kinetic intermediates reveal species specificity of penicillin-binding proteins. J. Mol. Biol. 322, 111-122 CrossRef PubMed
2. Fisher, J. F., Meroueh, S. O. and Mobashery, S. (2005) Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105, 395-424 CrossRef PubMed
3. Matagne, A., Dubus, A., Galleni, M. and Frere, J. M. (1999) The β-lactamase cycle: a tale of selective pressure and bacterial ingenuity. Nat. Prod. Rep. 16, 1-19 CrossRef PubMed
4. Sandanayaka, V. P. and Prashad, A. S. (2002) Resistance to β-lactam antibiotics: structure and mechanism based design of β-lactamase inhibitors. Curr. Med. Chem. 9, 1145-1165 CrossRef PubMed
5. Livermore, D. M. (1995) β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8, 557-584 PubMed
6. st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14, 933-951 CrossRef PubMed
7. Matagne, A., Lamotte-Brasseur, J. and Frere, J. M. (1998) Catalytic properties of class A β-lactamases: efficiency and diversity. Biochem. J. 330, 581-598 PubMed
8. Chaibi, E. B., Sirot, D., Paul, G. and Labia, R. (1999) Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43, 447-458 CrossRef PubMed
9. Paterson, D. L. and Bonomo, R. A. (2005) Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657-686 CrossRef PubMed
10. Hawkey, P. M. (2008) Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin. Microbiol. Infect. 14, 159-165 CrossRef PubMed
11. Bush, K. (2013) The ABCD's of β-lactamase nomenclature. J. Infect. Chemother. 19, 549-559 CrossRef PubMed
12. Watkins, R. R., Papp-Wallace, K. M., Drawz, S. M. and Bonomo, R. A. (2013) Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front. Microbiol. 4, 1-8 CrossRef PubMed
13. Abagyan, R. and Totrov, M. (2001) High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 5, 375-382 CrossRef PubMed
14. Powers, R. A., Morandi, F. and Shoichet, B. K. (2002) Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure 10, 1013-1023 CrossRef PubMed
15. Kitchen, D. B., Decornez, H., Furr, J. R. and Bajorath, J. (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3, 935-949 CrossRef PubMed
16. Schuttelkopf, A. W. and van Aalten, D. M. F. (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D 60, 1355-1363 CrossRef
17. Babaoglu, K., Simeonov, A., Lrwin, J. J., Nelson, M. E., Feng, B., Thomas, C. J., Cancian, L., Costi, M. P., Maltby, D. A., Jadhav, A. et al. (2008) Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase. J. Med. Chem. 51, 2502-2511 CrossRef PubMed
18. Coan, K. E. D., Maltby, D. A., Burlingame, A. L. and Shoichet, B. K. (2009) Promiscuous aggregate-based inhibitors promote enzyme unfolding. J. Med. Chem. 52, 2067-2075 CrossRef PubMed
19. Ocallagh, Ch, Shingler, A. H., Kirby, S. M. and Morris, A. (1972) Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1, 283-288 CrossRef PubMed
20. Chan, P. H., So, P. K., Ma, D. L., Zhao, Y., Lai, T. S., Chung, W. H., Chan, K. C., Yiu, K. F., Chan, H. W., Siu, F. M. et al. (2008) Fluorophore-labeled β-lactamase as a biosensor for β-lactam antibiotics: a study of the biosensing process. J. Am. Chem. Soc. 130, 6351-6361 CrossRef PubMed
21. Chan, P. H., Liu, H. B., Chen, Y. W., Chan, K. C., Tsang, C. W., Leung, Y. C. and Wong, K. Y. (2004) Rational design of a novel fluorescent biosensor for β-lactam antibiotics from a class A β-lactamase. J. Am. Chem. Soc. 126, 4074-4075 CrossRef PubMed
22. Benson, D. E., Conrad, D. W., de Lorimer, R. M., Trammell, S. A. and Hellinga, H. W. (2001) Design of bioelectronic interfaces by exploiting hinge-bending motions in proteins. Science 293, 1641-1644 CrossRef PubMed
23. Salins, L. L. E., Goldsmith, E. S., Ensor, C. M. and Daunert, S. (2002) A fluorescence-based sensing system for the environmental monitoring of nickel using the nickel binding protein from Escherichia coli. Anal. Bioanal. Chem. 372, 174-180 CrossRef PubMed
24. Shrestha, S., Salins, L. L. E., Ensor, C. M. and Daunert, S. (2002) Rationally designed fluorescently labeled sulfate-binding protein mutants: evaluation in the development of a sensing system for sulfate. Biotechnol. Bioeng. 78, 517-526 CrossRef PubMed
25. Lager, I., Fehr, M., Frommer, W. B. and Lalonde, S. W. (2003) Development of a fluorescent nanosensor for ribose. FEBS Lett. 553, 85-89 CrossRef PubMed
26. Ye, K. M. and Schultz, J. S. (2003) Genetic engineering of an allosterically based glucose indicator protein for continuous glucose monitoring by fluorescence resonance energy transfer. Anal. Chem. 75, 3451-3459 CrossRef PubMed
27. Leung, Y. C., Robinson, C. V., Aplin, R. T. and Waley, S. G. (1994) Site-directed mutagenesis of β-lactamase I: role of Glu166. Biochem. J. 299, 671-678 PubMed
28. Waley, S. G. (1974) A spectrophotometric assay of β-lactamase action on penicillins. Biochem. J. 139, 789-790 PubMed
29. Minami, S., Yotsuji, A., Inoue, M. and Mitsuhashi, S. (1980) Induction of β-lactamase by various β-lactam antibiotics in Enterobacter Cloacae. Antimicrob. Agents Chemother. 18, 382-385 CrossRef PubMed
30. Adachi, H., Ohta, T. and Matsuzawa, H. (1991) Site-directed mutants, at position 166, of RTEM-1 β-lactamase that form a stable acyl-enzyme intermediate with penicillin. J. Biol. Chem. 266, 3186-3191 PubMed
31. Sawai, T. and Tsukamoto, K. (1982) Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of β-lactamases produced by Gram-negative bacteria. J. Antibiot. 35, 1594-1602 CrossRef PubMed
32. Livermore, D. M. (1998) β-Lactamase-mediated resistance and opportunities for its control. J. Antimicrob. Chemother. 41, 25-41 CrossRef PubMed
33. Fisher, J., Belasco, J. G., Khosla, S. and Knowles, J. R. (1980) β-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. Biochemistry 19, 2895-2901 CrossRef PubMed
34. Reading, C. and Farmer, T. (1981) The inhibition of β-lactamases from Gram-negative bacteria by clavulanic acid. Biochem. J. 199, 779-787 PubMed
35. Imtiaz, U., Billings, E., Knox, J. R., Manavathu, E. K., Lerner, S. A. and Mobashery, S. (1993) Inactivation of class A β-lactamases by clavulanic acid: the role of arginine-244 in a proposed nonconcerted sequence of events. J. Am. Chem. Soc. 115, 4435-4442 CrossRef
36. McGovern, S. L., Helfand, B. T., Feng, B. and Shoichet, B. K. (2003) A specific mechanism of nonspecific inhibition. J. Med. Chem. 46, 4265-4272 CrossRef PubMed
37. McGovern, S. L. and Shoichet, B. K. (2003) Kinase inhibitors: not just for kinases anymore. J. Med. Chem. 46, 1478-1483 CrossRef PubMed
38. Seidler, J., McGovern, S. L., Doman, T. N. and Shoichet, B. K. (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477-4486 CrossRef PubMed
39. McGovern, S. L., Caselli, E., Grigorieff, N. and Shoichet, B. K. (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712-1722 CrossRef PubMed
40. Bush, K. and Sykes, R. B. (1986) Methodology for the study of β-lactamases. Antimicrob. Agents Chemother. 30, 6-10 CrossRef PubMed
41. Chan, P. H., Chan, K. C., Liu, H. B., Chung, W. H., Leung, Y. C. and Wong, K. Y. (2005) Fluorescein-labeled β-lactamase mutant for high-throughput screening of bacterial β-lactamases against β-lactam antibiotics. Anal. Chem. 77, 5268-5276 CrossRef PubMed